Andreas A Argyriou
Overview
Explore the profile of Andreas A Argyriou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
155
Citations
2444
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Argyriou A, Bruna J, Kalofonou F, Velasco R, Litsardopoulos P, Alemany M, et al.
J Peripher Nerv Syst
. 2024 Feb;
29(1):38-46.
PMID: 38311337
Objective: To define the incidence and risk factors for developing chemotherapy-induced neuropathic pain (CINP). Methods: Retrospective, file-based analysis on cancer patients who received any type of conventional chemotherapy and for...
12.
Dermitzakis E, Vikelis M, Xiromerisiou G, Rallis D, Soldatos P, Litsardopoulos P, et al.
J Clin Med
. 2024 Jan;
13(2).
PMID: 38256516
To investigate whether the incidence of triggers, prodromal symptoms, hypersensitivity symptoms accompanying headache and responses to triptans were modified during a continuous 9-month fremanezumab therapy for migraine prophylaxis. We studied...
13.
Alberti P, Argyriou A, Bruna J, Damaj M, Faithfull S, Harding A, et al.
Support Care Cancer
. 2024 Jan;
32(2):117.
PMID: 38244122
Purpose: This white paper provides guidance regarding the process for establishing and maintaining international collaborations to conduct oncology/neurology-focused chemotherapy-induced peripheral neurotoxicity (CIPN) research. Methods: An international multidisciplinary group of CIPN...
14.
Xiromerisiou G, Lampropoulos I, Dermitzakis E, Vikelis M, Marogianni C, Mysiris D, et al.
Toxins (Basel)
. 2023 Sep;
15(9).
PMID: 37755965
We sought to assess the efficacy of combining onabotulinumtoxinA (BoNTA) as add-on therapy to carbamazepine or oxcarbazepine in treatment-refractory patients with trigeminal neuralgia (TGN) who failed to respond (less than...
15.
Vikelis M, Dermitzakis E, Xiromerisiou G, Rallis D, Soldatos P, Litsardopoulos P, et al.
J Clin Med
. 2023 Jul;
12(13).
PMID: 37445560
Objective: this post hoc analysis aimed to evaluate the efficacy of fremanezumab in difficult-to-treat chronic migraine (CM) patients with and without psychiatric comorbidities (PCs), mainly anxiety and/or depression. Methods: We...
16.
Argyriou A, Dermitzakis E, Xiromerisiou G, Rallis D, Soldatos P, Litsardopoulos P, et al.
J Clin Med
. 2023 May;
12(9).
PMID: 37176658
Objective: To define, in a real-world population of patients with high-frequency episodic (HFEM) or chronic migraine (CM), the predictive role of socio-demographic or phenotypic profiling of responders to fremanezumab. Patients...
17.
Vikelis M, Argyriou A, Antoniou A, Spingos K, Skliros A, Bilias K, et al.
Medicina (Kaunas)
. 2023 Apr;
59(4).
PMID: 37109692
: Migraine is considered the most clinically important primary headache due to its high prevalence and significant burden. Although globally categorized as one of the leading causes of disability, it...
18.
Park S, Cetinkaya-Fisgin A, Argyriou A, Hoke A, Cavaletti G, Alberti P
J Neurol Neurosurg Psychiatry
. 2023 Apr;
94(11):962-972.
PMID: 37015772
Multiple pathological mechanisms are involved in the development of chemotherapy-induced peripheral neurotoxicity (CIPN). Recent work has provided insights into the molecular mechanisms underlying chemotherapy-induced axonal degeneration. This review integrates evidence...
19.
Argyriou A, Dermitzakis E, Xiromerisiou G, Rallis D, Soldatos P, Litsardopoulos P, et al.
Eur J Neurol
. 2023 Feb;
30(5):1435-1442.
PMID: 36773011
Objective: To prospectively assess the efficacy and safety of fremanezumab for migraine prophylaxis in patients with failure of at least three previous preventive treatments. Changes in disability as quality-of-life outcomes...
20.
Mantovani E, Zucchella C, Argyriou A, Tamburin S
Expert Rev Neurother
. 2023 Jan;
23(1):25-43.
PMID: 36701529
Introduction: Non-motor symptoms (NMS) affect patients with Parkinson's disease (PD) from the prodromal to the advanced stages. NMS phenotypes greatly vary and have a huge impact on patients' and caregivers'...